FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912621736> ?p ?o ?g. }

• W2912621736 endingPage "76" @default.
• W2912621736 startingPage "69" @default.
• W2912621736 abstract "This post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH FH).Data from 1257 patients with HeFH on maximally tolerated statin ± other lipid-lowering therapies were analyzed by an alirocumab dose regimen and by age subgroups (18 to < 45, 45 to < 55, 55 to < 65, and ≥ 65 years). In the FH I and II trials, patients received 75 mg subcutaneously every 2 weeks (Q2W), with dose increase to 150 mg Q2W at week 12 if week 8 low-density lipoprotein cholesterol (LDL-C) was ≥ 70 mg/dl. In HIGH FH and LONG TERM, patients received 150 mg alirocumab Q2W.Baseline characteristics were similar between treatment groups across all age groups; the proportion of males decreased whereas the proportion of patients with coronary heart disease, diabetes, hypertension, and declining renal function increased with increasing age. Mean LDL-C reductions at week 24 were consistent across age groups (50.6-61.0% and 51.1-65.8% vs. placebo for the 75/150 and 150 mg alirocumab dose regimens, respectively; both non-significant interaction P-values). Treatment-emergent adverse events occurred in similar frequency in alirocumab- and placebo-treated patients regardless of age, except for injection-site reactions, which were more common in alirocumab than placebo but declined in frequency with age.Alirocumab treatment resulted in significant LDL-C reductions at weeks 12 and 24 and was generally well tolerated in patients with HeFH across all age groups studied." @default.
• W2912621736 created "2019-02-21" @default.
• W2912621736 creator A5003747242 @default.
• W2912621736 creator A5004099465 @default.
• W2912621736 creator A5007048045 @default.
• W2912621736 creator A5007729877 @default.
• W2912621736 creator A5009182471 @default.
• W2912621736 creator A5014172894 @default.
• W2912621736 creator A5044425699 @default.
• W2912621736 creator A5053901502 @default.
• W2912621736 creator A5063601469 @default.
• W2912621736 creator A5066931153 @default.
• W2912621736 date "2019-02-01" @default.
• W2912621736 modified "2023-09-23" @default.
• W2912621736 title "Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia" @default.
• W2912621736 cites W1962272706 @default.
• W2912621736 cites W2001328643 @default.
• W2912621736 cites W2121568629 @default.
• W2912621736 cites W2165624352 @default.
• W2912621736 cites W2509676484 @default.
• W2912621736 cites W2514978490 @default.
• W2912621736 cites W2519905430 @default.
• W2912621736 cites W2530537701 @default.
• W2912621736 cites W2564712078 @default.
• W2912621736 cites W2596179513 @default.
• W2912621736 cites W2751210700 @default.
• W2912621736 cites W2751933740 @default.
• W2912621736 cites W2757199879 @default.
• W2912621736 cites W2809173176 @default.
• W2912621736 cites W2900034165 @default.
• W2912621736 cites W3006057482 @default.
• W2912621736 cites W4211152466 @default.
• W2912621736 doi "https://doi.org/10.1007/s10557-019-06852-6" @default.
• W2912621736 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6433806" @default.
• W2912621736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30734207" @default.
• W2912621736 hasPublicationYear "2019" @default.
• W2912621736 type Work @default.
• W2912621736 sameAs 2912621736 @default.
• W2912621736 citedByCount "11" @default.
• W2912621736 countsByYear W29126217362019 @default.
• W2912621736 countsByYear W29126217362020 @default.
• W2912621736 countsByYear W29126217362021 @default.
• W2912621736 countsByYear W29126217362022 @default.
• W2912621736 countsByYear W29126217362023 @default.
• W2912621736 crossrefType "journal-article" @default.
• W2912621736 hasAuthorship W2912621736A5003747242 @default.
• W2912621736 hasAuthorship W2912621736A5004099465 @default.
• W2912621736 hasAuthorship W2912621736A5007048045 @default.
• W2912621736 hasAuthorship W2912621736A5007729877 @default.
• W2912621736 hasAuthorship W2912621736A5009182471 @default.
• W2912621736 hasAuthorship W2912621736A5014172894 @default.
• W2912621736 hasAuthorship W2912621736A5044425699 @default.
• W2912621736 hasAuthorship W2912621736A5053901502 @default.
• W2912621736 hasAuthorship W2912621736A5063601469 @default.
• W2912621736 hasAuthorship W2912621736A5066931153 @default.
• W2912621736 hasBestOaLocation W29126217361 @default.
• W2912621736 hasConcept C126322002 @default.
• W2912621736 hasConcept C142724271 @default.
• W2912621736 hasConcept C197934379 @default.
• W2912621736 hasConcept C204787440 @default.
• W2912621736 hasConcept C27081682 @default.
• W2912621736 hasConcept C2778163477 @default.
• W2912621736 hasConcept C2779120738 @default.
• W2912621736 hasConcept C2780072125 @default.
• W2912621736 hasConcept C2780745583 @default.
• W2912621736 hasConcept C2780902209 @default.
• W2912621736 hasConcept C2780948078 @default.
• W2912621736 hasConcept C2781413609 @default.
• W2912621736 hasConcept C43554185 @default.
• W2912621736 hasConcept C71924100 @default.
• W2912621736 hasConceptScore W2912621736C126322002 @default.
• W2912621736 hasConceptScore W2912621736C142724271 @default.
• W2912621736 hasConceptScore W2912621736C197934379 @default.
• W2912621736 hasConceptScore W2912621736C204787440 @default.
• W2912621736 hasConceptScore W2912621736C27081682 @default.
• W2912621736 hasConceptScore W2912621736C2778163477 @default.
• W2912621736 hasConceptScore W2912621736C2779120738 @default.
• W2912621736 hasConceptScore W2912621736C2780072125 @default.
• W2912621736 hasConceptScore W2912621736C2780745583 @default.
• W2912621736 hasConceptScore W2912621736C2780902209 @default.
• W2912621736 hasConceptScore W2912621736C2780948078 @default.
• W2912621736 hasConceptScore W2912621736C2781413609 @default.
• W2912621736 hasConceptScore W2912621736C43554185 @default.
• W2912621736 hasConceptScore W2912621736C71924100 @default.
• W2912621736 hasFunder F4320307781 @default.
• W2912621736 hasIssue "1" @default.
• W2912621736 hasLocation W29126217361 @default.
• W2912621736 hasLocation W29126217362 @default.
• W2912621736 hasLocation W29126217363 @default.
• W2912621736 hasLocation W29126217364 @default.
• W2912621736 hasOpenAccess W2912621736 @default.
• W2912621736 hasPrimaryLocation W29126217361 @default.
• W2912621736 hasRelatedWork W1910198985 @default.
• W2912621736 hasRelatedWork W2046996117 @default.
• W2912621736 hasRelatedWork W2054572833 @default.
• W2912621736 hasRelatedWork W2162657286 @default.
• W2912621736 hasRelatedWork W2585426472 @default.
• W2912621736 hasRelatedWork W2620969414 @default.

• next